doi:10.1016/j.gene.2021.145407 Chew A, Buck EA, Peretz S, Sirugo G, Rinaldo P, Isaya G
Zhang, Jiping
The two approaches converge on a common endpoint, reducing the burden of cellular senescence, through complementary upstream mechanisms
Unadjusted analysis found relatively higher (4 and 5.4% additional) weight loss, HbA1c (0.4% additional) reduction, and fewer gastrointestinal side effects with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg [25]
By Suzanne Fenske, MD, FACOG, ABOIM, MSCP GLP-1 receptor agonist medications, including semaglutide (Ozempic), tirzepatide (Monjaro), and liraglutide (Victoza), are FDA-approved for weight loss and diabetes